These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38811268)

  • 1. Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Luo H; Ma Y; Bi J; Li Z; Wang Y; Su Z; Gerstweiler L; Ren Y; Zhang S
    Vaccine; 2024 May; ():. PubMed ID: 38811268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.
    Zhao Y; Li Z; Voyer J; Li Y; Chen X
    ACS Appl Mater Interfaces; 2022 May; 14(19):21872-21885. PubMed ID: 35467839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation.
    Zhang B; Yin S; Wang Y; Su Z; Bi J
    Eng Life Sci; 2021 Jun; 21(6):438-452. PubMed ID: 34140854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of self-assembling properties of HBc-VLP derivatives aided by molecular dynamic simulations from a thermodynamic perspective.
    Luo H; Ma Y; Ren Y; Li Z; Sheng Y; Wang Y; Su Z; Bi J; Zhang S
    J Biomol Struct Dyn; 2023 Oct; ():1-14. PubMed ID: 37908124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Expression of Tandem-HBc Virus-Like Particles (VLPs).
    Stephen SL; Beales L; Peyret H; Roe A; Stonehouse NJ; Rowlands DJ
    Methods Mol Biol; 2018; 1776():97-123. PubMed ID: 29869237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system.
    Armero-Gimenez J; Wilbers R; Schots A; Williams C; Finnern R
    Front Immunol; 2023; 14():1088852. PubMed ID: 36776898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
    Sani MZ; Bargahi A; Momenzadeh N; Dehghani P; Moghadam MV; Maleki SJ; Nabipour I; Shirkani A; Akhtari J; Hesamizadeh K; Heidari S; Omrani F; Akbarzadeh S; Mohammadi M
    Appl Microbiol Biotechnol; 2021 Jan; 105(1):77-91. PubMed ID: 33215260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
    Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.
    Moradi Vahdat M; Hemmati F; Ghorbani A; Rutkowska D; Afsharifar A; Eskandari MH; Rezaei N; Niazi A
    Biotechnol Rep (Amst); 2021 Mar; 29():e00605. PubMed ID: 33732633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles.
    Tang S; Xuan B; Ye X; Huang Z; Qian Z
    Sci Rep; 2016 May; 6():25741. PubMed ID: 27170066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
    Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
    Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
    Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.
    Pumpens P; Razanskas R; Pushko P; Renhof R; Gusars I; Skrastina D; Ose V; Borisova G; Sominskaya I; Petrovskis I; Jansons J; Sasnauskas K
    Intervirology; 2002; 45(1):24-32. PubMed ID: 11937768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis.
    Aston-Deaville S; Carlsson E; Saleem M; Thistlethwaite A; Chan H; Maharjan S; Facchetti A; Feavers IM; Alistair Siebert C; Collins RF; Roseman A; Derrick JP
    Vaccine; 2020 Apr; 38(16):3201-3209. PubMed ID: 32178907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Vaccine Efficacy Boosted by Engineering Human Heavy Chain Ferritin and Chimeric Hepatitis B Virus Core Nanoparticles.
    Qu Y; Zhang B; Wang Y; Yin S; Sun Y; Middelberg A; Bi J
    ACS Appl Bio Mater; 2021 Sep; 4(9):7147-7156. PubMed ID: 35006946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
    Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
    Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.